Literature DB >> 8626810

Shedding of human thyrotropin receptor ectodomain. Involvement of a matrix metalloprotease.

J Couet1, S Sar, A Jolivet, M T Hai, E Milgrom, M Misrahi.   

Abstract

The thyrotropin (TSH) receptor in human thyroid glands has been shown to be cleaved into an extracellular alpha subunit and a transmembrane beta subunit held together by disulfide bridges. An excess of the latter component relative to the former suggested the shedding of the ectodomain. Indeed we observed such a shedding in cultures of human thyrocytes and permanently transfected L or Chinese hamster ovary cells. The shedding was increased by inhibitors of endocytosis, recycling, and lysosomal degradation, suggesting that it was dependent on receptor residency at the cell surface. It was slightly increased by TSH and phorbol esters, whereas forskolin and 8-bromo-cyclic AMP were without effect. Decreasing the serum concentration in cell culture medium enhanced the shedding by an unknown mechanism. The shedding of the TSH receptor alpha domain is the consequence of two events: cleavage of the receptor into alpha and beta subunits and reduction of the disulfide bridge(s). The complete inhibition of soluble TSH receptor shedding by the specific inhibitor BB-2116 indicated that the cleavage reaction is catalyzed probably at the cell surface by a matrix metalloprotease. This shedding mechanism may be responsible for the presence of soluble TSH receptor alpha subunit in human circulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626810     DOI: 10.1074/jbc.271.8.4545

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Thyroid autoimmunity.

Authors:  B Rapoport; S M McLachlan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  A monoclonal thyroid-stimulating antibody.

Authors:  Takao Ando; Rauf Latif; Alla Pritsker; Thomas Moran; Yuji Nagayama; Terry F Davies
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  The TSH receptor reveals itself.

Authors:  Terry Davies; Russell Marians; Rauf Latif
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 4.  Molecular and cellular mechanisms of ectodomain shedding.

Authors:  Kazutaka Hayashida; Allison H Bartlett; Ye Chen; Pyong Woo Park
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

Review 5.  The cell biology of the thyroid-disrupting mechanism of dichlorodiphenyltrichloroethane (DDT).

Authors:  M Rossi; A R Taddei; I Fasciani; R Maggio; F Giorgi
Journal:  J Endocrinol Invest       Date:  2017-06-21       Impact factor: 4.256

Review 6.  Review and hypothesis: does Graves' disease develop in non-human great apes?

Authors:  Sandra M McLachlan; Kristine Alpi; Basil Rapoport
Journal:  Thyroid       Date:  2011-11-08       Impact factor: 6.568

7.  Molecular characterization and analysis of a truncated serotonin receptor gene expressed in neural and reproductive tissues of abalone.

Authors:  Sasiporn Panasophonkul; Somjai Apisawetakan; Scott F Cummins; Patrick S York; Bernard M Degnan; Peter J Hanna; Porncharn Saitongdee; Prasert Sobhon; Prapee Sretarugsa
Journal:  Histochem Cell Biol       Date:  2009-02-13       Impact factor: 4.304

Review 8.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

9.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 10.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.